Make an enquiry
Refer a patient
Patient Portal
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
2021-06-09T00:00:00.000+01:00
Ongoing

KEYNOTE-992

KEYNOTE-992
Bladder cancer

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Chemoradiotherapy (CRT) Versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC)

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Chemoradiotherapy (CRT) Versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC)

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Bladder

Study Phase

III

Trial Identifiers

Registration number: NCT04241185

https://www.clinicaltrials.gov/study/NCT04241185

GenesisCare Location(s)

North Shore 

North Shore  :::
Principal Investigator(s)

Dr Laurence Krieger

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.